Table 1.

Response details for patients treated with anti-EGFR antibody therapy.

Class	BRAF	Line	Regimen	Response	PFS
2	G469V	1	FOLFOX+Pmab	PR	18.9
2	T599_V600TinsT	1	FOLFOX+Pmab	PD	1.2
2	G469A	2	Irinotecan+Pmab	SD	4.0*
2	G469A	2	Irinotecan+Cmab	SD	3.5*
2	L597R	2	Irinotecan+Pmab	PD	3.3
2	L597R	2	FOLFIRI+Pmab	SD	16.5
2	G469A	3	FOLFIRI**+Cmab	SD	4.4
2	G469A	3	Cmab	SD	2.8
2	G469V	3	Irinotecan**+Cmab	SD	10.9
2	L485F	3	Irinotecan**+Cmab	SD	6.3
2	L525R	3	Cmab	SD	4
2	K601E	3	Pmab	PD	1.4
Class	BRAF	Line	Regimen	Response	PFS
3	N581I	1	Irinotecan+Cmab	SD	10.3*
3	N581S	1	FOLFIRI+Cmab	PR	16
3	N581T	1	FOLFOX+Pmab	PR	1.4*
3	D594G	1	FOLFOX+Pmab	SD	7.0*
3	D594G	1	FOLFOX+Pmab	PR	2.8*
3	D594G	1	FOLFOX+Pmab	PR	8.3*
3	F595L	1	FOLFOX+Pmab	PR	10.2*
3	G466E	2	Irinotecan**+Pmab	PR	8.3*
3	D594G	2	FOLFIRI+Cmab	PR	3.2
3	G466E	3	Irinotecan**+Pmab	PR	8.3
3	G466V	3	Irinotecan**+Pmab	PR	6.1
3	Q524L	3	Pmab	PD	2.3
3	D594G	3	Irinotecan**+Pmab	NE	1.8*
3	D594G	3	Irinotecan**+Pmab	SD	1.8*
3	D594G	3	FOLFIRI**+Cmab	SD	3.6
3	D594G	3	Irinotecan**+Pmab	PD	2.8
3	D594G	3	FOLFIRI**+Cmab	PD	2.4
3	D594G	3	FOLFIRI**+Pmab	SD	2.6*
3	D594G	3	FOLFIRI**+Cmab	SD	3.7
3	D594G	3	Irinotecan**+Cmab	SD	6.6
3	D594G	3	Irinotecan**+Pmab	SD	2.3
3	D594G	3	Irinotecan**+Cmab	SD	2.2*
3	D594G	3	Irinotecan**+Pmab	PR	6.7*
3	D594N	3	Irinotecan**+Pmab	PR	14.9
3	D594N	3	5-FU***+Cmab	PD	1.6
3	D594N	5	Irinotecan**+Pmab	PR	14.7*
3	F247L	3	FOLFIRI**+Cmab	CR	12.6
3	R558Q	4	Irinotecan**+Cmab	CR	37.7*

CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; Cmab, Cetuximab; Pmab, Panitumumab.

^*censored

^**Irinotecan refractory

^***5-FU refractory